MX2017004046A - Derivados de acido boronico. - Google Patents
Derivados de acido boronico.Info
- Publication number
- MX2017004046A MX2017004046A MX2017004046A MX2017004046A MX2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A MX 2017004046 A MX2017004046 A MX 2017004046A
- Authority
- MX
- Mexico
- Prior art keywords
- acid derivatives
- boronic acid
- abnomality
- lmp7
- inhibitors
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos de la fórmula (I) son inhibidores de LMP7 y se pueden emplear, inter alia, para el tratamiento de una anormalidad de trastorno autoinmunitario o malignidades hematológicas. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003392 | 2014-10-01 | ||
| PCT/EP2015/002008 WO2016050359A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004046A true MX2017004046A (es) | 2017-06-19 |
| MX370336B MX370336B (es) | 2019-12-10 |
Family
ID=51690789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004046A MX370336B (es) | 2014-10-01 | 2015-10-01 | Derivados de acido boronico. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10294246B2 (es) |
| EP (1) | EP3201207B1 (es) |
| JP (1) | JP6835711B2 (es) |
| KR (1) | KR102450583B1 (es) |
| CN (1) | CN107001390B (es) |
| AU (1) | AU2015327346B2 (es) |
| BR (1) | BR112017006420A2 (es) |
| CA (1) | CA2963205A1 (es) |
| ES (1) | ES2873000T3 (es) |
| IL (1) | IL251301B (es) |
| MX (1) | MX370336B (es) |
| RU (1) | RU2017115188A (es) |
| SG (1) | SG11201702623TA (es) |
| WO (1) | WO2016050359A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963198A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| WO2016050355A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| SG11201702628XA (en) | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
| CN111183142B (zh) * | 2017-08-24 | 2023-06-16 | 默克专利股份公司 | 硼酸衍生物 |
| DK3826723T3 (da) * | 2018-07-26 | 2024-01-15 | Merck Patent Gmbh | Boronsyrederivater |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| EP4301466A1 (en) * | 2021-03-02 | 2024-01-10 | Case Western Reserve University | B-lactamase inhibitors and uses thereof |
| IL310390A (en) | 2021-07-29 | 2024-03-01 | Merck Patent Gmbh | Crystalline forms of [(R1)-2-benzofuran-3-yl)-1-{[(R4, R2, S1)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, Their adducts and their use |
| WO2023061445A1 (zh) * | 2021-10-14 | 2023-04-20 | 首药控股(北京)股份有限公司 | 硼酸衍生物 |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| US7271186B1 (en) * | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| US20100286092A1 (en) * | 2007-11-13 | 2010-11-11 | Burns Christopher J | Beta-lactamase inhibitors |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| MX352652B (es) * | 2011-12-22 | 2017-12-04 | Ares Trading Sa | Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico. |
| CA2963198A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| WO2016050355A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| SG11201702628XA (en) | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
-
2015
- 2015-10-01 MX MX2017004046A patent/MX370336B/es active IP Right Grant
- 2015-10-01 CA CA2963205A patent/CA2963205A1/en active Pending
- 2015-10-01 CN CN201580053425.1A patent/CN107001390B/zh active Active
- 2015-10-01 JP JP2017518100A patent/JP6835711B2/ja active Active
- 2015-10-01 BR BR112017006420A patent/BR112017006420A2/pt active Search and Examination
- 2015-10-01 WO PCT/EP2015/002008 patent/WO2016050359A1/en active Application Filing
- 2015-10-01 RU RU2017115188A patent/RU2017115188A/ru not_active Application Discontinuation
- 2015-10-01 KR KR1020177011643A patent/KR102450583B1/ko active IP Right Grant
- 2015-10-01 US US15/516,424 patent/US10294246B2/en active Active
- 2015-10-01 ES ES15780765T patent/ES2873000T3/es active Active
- 2015-10-01 SG SG11201702623TA patent/SG11201702623TA/en unknown
- 2015-10-01 AU AU2015327346A patent/AU2015327346B2/en active Active
- 2015-10-01 EP EP15780765.2A patent/EP3201207B1/en active Active
-
2017
- 2017-03-21 IL IL251301A patent/IL251301B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017115188A3 (es) | 2019-03-29 |
| EP3201207B1 (en) | 2021-02-24 |
| MX370336B (es) | 2019-12-10 |
| CN107001390B (zh) | 2020-11-27 |
| US20180105539A1 (en) | 2018-04-19 |
| KR102450583B1 (ko) | 2022-10-04 |
| WO2016050359A1 (en) | 2016-04-07 |
| CA2963205A1 (en) | 2016-04-07 |
| BR112017006420A2 (pt) | 2017-12-19 |
| JP6835711B2 (ja) | 2021-02-24 |
| AU2015327346A1 (en) | 2017-05-18 |
| CN107001390A (zh) | 2017-08-01 |
| EP3201207A1 (en) | 2017-08-09 |
| IL251301B (en) | 2022-02-01 |
| JP2017536335A (ja) | 2017-12-07 |
| KR20170062517A (ko) | 2017-06-07 |
| ES2873000T3 (es) | 2021-11-03 |
| RU2017115188A (ru) | 2018-11-06 |
| IL251301A0 (en) | 2017-05-29 |
| AU2015327346B2 (en) | 2019-12-05 |
| SG11201702623TA (en) | 2017-04-27 |
| US10294246B2 (en) | 2019-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500293A1 (en) | Boronic acid derivatives | |
| MX2017004043A (es) | Derivados de acido boronico. | |
| MX2017004037A (es) | Derivados de acido boronico. | |
| MX370336B (es) | Derivados de acido boronico. | |
| IL259787A (en) | Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
| MX2016012829A (es) | Inhibidores de biaril cinasa. | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| IL261717A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| PH12017500745A1 (en) | Bromodomain inhibitors | |
| NZ730603A (en) | Mk2 inhibitors and uses thereof | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| PH12017501071A1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| SG10201900564WA (en) | Methods for treating cancer | |
| MX366765B (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. | |
| MA39824A (fr) | Composés azole amido-substitués | |
| MX2016002924A (es) | Inhibidores de cinasa a base de eter arilico. | |
| MX2016009355A (es) | Inhibidores de aril lactama cinasa. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| TN2016000180A1 (en) | Novel compound for treatment of severe hypoglycemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |